Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.78 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | UNG | P13051 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzaldehyde SCHEMBL9075999 | 0.97 | ALDH1A1 (0.74) | ALDH1A1CYP2A6CYP2A13TSHRRELA | |
| Benzaldehyde SCHEMBL27599293 | 0.91 | ALDH1A1 (0.64) | ALDH1A1CYP2A6CYP2A13TSHRRELA | |
| Benzaldehyde SCHEMBL27957434 | 0.90 | ALDH1A1 (0.70) | ALDH1A1CYP2A6CYP2A13TSHRRELA | |
| Benzaldehyde SCHEMBL11223342 | 0.90 | ALDH1A1 (0.70) | ALDH1A1CYP2A6CYP2A13TSHRRELA | |
| Benzaldehyde SCHEMBL29291303 | 0.88 | ALDH1A1 (0.88) | ALDH1A1CYP2A6TSHRLMNATRPA1 | |
| Benzaldehyde SCHEMBL27780794 | 0.88 | ALDH1A1 (0.88) | ALDH1A1CYP2A6CYP2A13TSHRLMNA | |
| Benzaldehyde SCHEMBL1330097 | 0.88 | — | — | |
| Benzaldehyde SCHEMBL9236967 | 0.88 | — | — | |
| Benzaldehyde SCHEMBL10051945 | 0.88 | — | — | |
| Benzaldehyde SCHEMBL22400699 | 0.88 | ALDH1A1 (1.00) | ALDH1A1CYP2A6TSHRLMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987382-B2 | Radiotracer compositions | GE HEALTHCARE LIMITED (GB) | 2018-06-05 | — | — | US | claimed |
| CN-104031139-B | Be used for positron medicine of Alzheimer disease PET imaging and preparation method thereof | THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XI'AN JIAOTONG UNIVERSITY (CN) | 2016-05-04 | — | — | CN | claimed |
| CN-104800865-A | Targeted positron tracer for realizing PET (Positron Emission Tomography) imaging of positive tumors for HER2 (Human Epidermal Growth Factor Receptor 2) expression, and preparation method of targeted positron tracer | FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XI AN JIAOTONG UNIV | 2015-07-29 | — | — | CN | claimed |
| CN-104031139-A | Positive electron medicine for alzheimers disease PET (Positron Emission Tomography) imaging and preparation method of positive electron medicine | FIRST AFFILIATED HOSPITAL MEDICAL COLLEGE XI AN JIAOTONG UNIV | 2014-09-10 | — | — | CN | claimed |
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-05-31 | — | — | US | claimed |
| EP-2648767-B1 | RADIOTRACER COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2023-03-15 | — | — | EP | disclosed |
| US-20220202965-A1 | RADIOTRACER COMPOSITIONS AND METHODS | GE HEALTHCARE LTD (GB) | 2022-06-30 | — | — | US | disclosed |
| EP-2761514-B1 | METHOD OF OPERATING AN AUTOMATED RADIOPHARMACEUTICAL SYNTHESIZER | GE HEALTHCARE LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| US-10758887-B2 | Method of operating an automated radiopharmaceutical synthesizer | GE HEALTHCARE LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| CN-105848687-B | Radiotracer compositions and methods | 通用电气健康护理有限公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20190001296-A1 | METHOD OF OPERATING AN AUTOMATED RADIOPHARMACEUTICAL SYNTHESIZER | GE HEALTHCARE LIMITED (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10029228-B2 | Method of operating an automated radiopharmaceutical synthesizer | GE HEALTHCARE LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| WO-2013048954-A1 | METHOD OF OPERATING AN AUTOMATED RADIOPHARMACEUTICAL SYNTHESIZER | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012076697-A1 | RADIOTRACER COMPOSITIONS | GE HEALTHCARE LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| CN-101065152-A | Contrast agents targeting urokinase plasminogen activator receptor | GE HEALTHCARE AS (NO) | 2007-10-31 | — | — | CN | disclosed |
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-05-31 | — | — | US | disclosed |
| EP-0692982-A4 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | DU PONT MERCK PHARMA (US) | 1998-03-11 | — | — | EP | disclosed |
| CN-1122577-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | DU PONT MERCK PHARMA (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0692982-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202965-A1 | RADIOTRACER COMPOSITIONS AND METHODS | MET, METTL14, MEN1 | ALDH1A1 4112/4885CYP2A6 4220/4885CYP2A13 4040/4885 |
| US-20070122341-A1 | Benzylideneaniline derivatives and their radioisotope labeled compounds for binding and imaging of beta-amyloid plaques | APP, BACE1, APBA1 | ALDH1A1 2630/4885CYP2A6 1888/4885CYP2A13 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.